MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Balance Sheets Overview

Current Ratio
1041.63%
Quick Ratio
1041.63%
Cash Ratio
55.32%
Debt to Asset Ratio
17.53%
Unit: Thousand (K) dollars
Assets Breakdown
    • Short-term investments
    • Long-term investments
    • Cash and cash equivalents
Liabilities Breakdown
    • Capital in excess of par value
    • Accumulated deficit
    • Liabilities related to the sales...
    • Others
Balance Sheets
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Cash and cash equivalents
39,267
149,578
15,116
41,032
Short-term investments
645,074
419,026
230,636
229,176
Other current assets (including 0 and 429 as of june 30, 2026 and december 31, 2025, respectively, from a related party)
55,061
20,437
20,514
11,149
Total current assets
739,402
589,041
266,266
281,357
Long-term investments
339,061
162,993
0
0
Property, plant and equipment, net
-
-
2,060
2,826
Operating lease right-of-use assets
-
-
2,941
7,171
Equity method investment in gannet biochem
-
-
3,491
4,837
Other assets
16,666
11,237
5,648
5,156
Total assets
1,095,129
763,271
280,406
301,347
Accounts payable (including 456 and 137 as of june 30, 2026 and december 31, 2025, respectively, to a related party)
24,891
10,026
10,770
15,563
Accrued expenses (including 130 and 994 as of june 30, 2026 and december 31, 2025, respectively, to a related party)
23,388
25,151
22,271
28,594
Operating lease liabilities, current portion
22,706
22,531
20,495
22,183
Total current liabilities
70,985
57,708
53,536
66,340
Operating lease liabilities, less current portion
55,850
60,631
65,256
69,732
Liabilities related to the sales of future royalties ending balance
-
-
63,971
-
Less unamortized transaction costs
-
-
814
-
Liabilities related to the sales of future royalties, net
57,378
60,270
63,157
75,164
Other long-term liabilities
7,795
8,446
8,625
5,025
Total liabilities
192,008
187,055
190,574
216,261
Common stock, 0.0001 par value 390,000,000 shares authorized 34,129,664 shares and 20,378,832 shares issued and outstanding at june 30, 2026 and december 31, 2025, respectively
3
3
2
2
Capital in excess of par value
4,750,686
4,382,437
3,850,099
3,809,235
Treasury stock, at cost 0 shares and 552,307 shares as of september 30, 2025 and december 31, 2024, respectively
-
-
-
0
Accumulated other comprehensive income (loss)
-1,756
-1,034
17
56
Accumulated deficit
-3,845,812
-3,805,190
-3,760,286
-3,724,207
Total stockholders' equity
903,121
576,216
89,832
85,086
Total liabilities and stockholders' equity
1,095,129
763,271
280,406
301,347
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Short-term investments$645,074K (385.33%↑ Y/Y)Other current assets(including 0 and 429 as of...$55,061K (416.37%↑ Y/Y)Cash and cashequivalents$39,267K (-8.66%↓ Y/Y)Total current assets$739,402K (296.32%↑ Y/Y)Long-term investments$339,061K Other assets$16,666K (231.73%↑ Y/Y)Total assets$1,095,129K (427.69%↑ Y/Y)Total liabilities andstockholders' equity$1,095,129K (427.69%↑ Y/Y)Total stockholders'equity$903,121K (3830.21%↑ Y/Y)Total liabilities$192,008K (-17.15%↓ Y/Y)Accumulated deficit-$3,845,812K (-4.26%↓ Y/Y)Accumulated othercomprehensive income (loss)-$1,756K (-12442.86%↓ Y/Y)Capital in excess of parvalue$4,750,686K (29.54%↑ Y/Y)Total currentliabilities$70,985K (-0.57%↓ Y/Y)Liabilities related to thesales of future...$57,378K (-28.79%↓ Y/Y)Operating leaseliabilities, less current...$55,850K (-24.67%↓ Y/Y)Other long-termliabilities$7,795K (38.31%↑ Y/Y)Common stock, 0.0001par value...$3K (200.00%↑ Y/Y)Accounts payable(including 456 and 137 as of...$24,891K (74.29%↑ Y/Y)Accrued expenses(including 130 and 994 as of...$23,388K (-33.37%↓ Y/Y)Operating leaseliabilities, current portion$22,706K (3.16%↑ Y/Y)

NEKTAR THERAPEUTICS (NKTR)

NEKTAR THERAPEUTICS (NKTR)